Study 2 is a modified in vivo drug efficacy study in the age group directly affected by IPTi, namely 2-10 months of age. Asymptomatic children will be followed up at days 1, 2, 3,7,14, 21 and 28 only. Endpoint is day 28 recrudescence rate. Blood slide and filter paper will only be taken on day 7, 14 and 28 unless the child has a fever or has reported fever in the last 48 hours.